• Home
  • /
  • Fund Detail
110023

E Fund Healthcare Industry Hybrid Fund

110023

E Fund Healthcare Industry Hybrid Fund

  • Daily NAV and Return
  • Basic Information
  • Portfolio Managers
  • Fee Structure
  • Asset Allocation
  • Historical Daily NAV
  • Risk Disclaimer
3.450
NAV(RMB)
1.26%
Daily Return
Date:2025-04-30
Return: 0.00% Max. Drawdown: 0.00%
Basic Information
Fund Name: E Fund Healthcare Industry Hybrid Fund
Fund Name (Short name): E Fund Healthcare Industry Hybrid Fund
Fund Code: 110023
Inception Date: 2011-01-28
Fund Manager: E Fund Management Co., Ltd.
Portfolio Managers: Zhenxiao Yang
Custodian: Bank of China
Net Asset Value: As of 31/03/2025: RMB 4,475,203,433.07
Investment Scope:

The Fund may invest in financial instruments with good liquidity, including legally issued and listed on China’s mainland exchanges (including depositary receipts), bonds, warrants, asset-backed securities, money market instruments, stock index futures, and other financial instruments as allowed by Laws and Regulations or CSRC. The Fund may invest in stocks (including depository receipts) issued and listed on the STAR Market and bonds issued by companies listed on the STAR Market.
The Fund may also invest in other financial instruments that are permitted to be invested by a fund in the future by Laws and Regulations or CSRC after fulfilling the relevant formalities in accordance with relevant Laws and Regulations or the requirements of CSRC.

Portfolio Allocation: This Fund is a hybrid fund with stocks accounting for 60% to 95% of the Net Asset Value. Cash and government bonds maturing within one year shall not be less than 5% of the Net Asset Value, where cash excludes settlement provisions, deposited margins, or Subscription receivables, etc. The proportion of warrants, stock index futures, and other financial instruments in the investment portfolio shall be compliant with the provisions of Laws and Regulations or the rules set by regulatory authorities. The Fund will invest not less than 85% of its stock assets in stocks in the pharmaceutical and biological industry as defined by SWS Research Co., Ltd. ("SWS").
Investment Objective: The Fund mainly invests in healthcare industry stocks and aims to pursue investment returns that exceed performance benchmark under the premise of strict risk control.
Benchmark: SWS Pharmaceutical and Biological Industry Index Return × 80% + ChinaBond Total Index Return × 20%
Portfolio Managers
Zhenxiao Yang
Fee Structure
Subscription Fee
Subscription Amount M (RMB) (inclusive of Subscription fee) Subscription Fee Rate
M<1 million 1.50%
1 million≤M<5 million 1.20%
5 million≤M<10 million 0.30%
M≥10 million RMB 1000.00 per transaction
Note: In the case where the subscription fee is tiered by amount, if an investor makes multiple subscriptions, the subscription fee will be applied according to the rate corresponding to the amount of each individual subscription.
Redemption Fee
Holding Period (days) Redemption Fee Rate
0-6 1.50%
7-364 0.50%
365-729 0.25%
730 days or more 0.00%
Management Fee and Custody Fee
Management Fee 1.20%
Custody Fee 0.20%
Note: 1. The annual fee amounts in the table above are for the overall fund expenses, not the expenses for individual share classes. Moreover, the annual fee amounts are estimated values, and the final actual amounts are subject to the disclosures in the periodic reports of the fund. 2. The expenses and tax liabilities incurred by this fund from trading securities, funds, etc., are deducted from the fund assets based on the actual amounts incurred.
Asset Allocation
Type of asset Amount(RMB) % of Total Asset of the Fund
Equity Investment 4,596,517,625.90 93.29%
Bank Deposit and Settlement Reserve 314,257,639.08 6.38%
Others 16,094,040.12 0.33%
Total 4,926,869,305.10 100.00%
Total Asset: 0 !
Net Asset Value (NAV) = Total Asset Value - Total Liability. There could be difference between total asset value and net asset value due to the possible liability (e,g, payable). All numbers are calculated on fund level.
Top 10 Stock Holding(57.5%)
Stock Name Stock Code Number of Shares % of NAV
APT Medical Inc. 688617 1,085,684 8.60%
Jiangsu Hengrui Pharmaceuticals Co.,Ltd 600276 7,606,289 7.65%
Hangzhou Tigermed Consulting Co., Ltd 300347 6,191,769 6.43%
Joinn Laboratories (China) Co.,Ltd. 603127 13,832,379 5.75%
新诺威 300765 7,190,435 5.49%
Eyebright Medical Technology (Beijing) Co., Ltd. 688050 2,591,876 5.19%
Beijing Hotgen Biotech Co.,Ltd. 688068 2,648,852 5.17%
海思科 002653 6,529,300 5.08%
科伦药业 002422 6,369,697 4.20%
Shenzhen New Industries Biomedical Engineering Co.,Ltd. 300832 3,310,333 3.94%
Risk Disclaimer

Dear Investors,

Please be advised that investment inherently carries risks, and it is recommended to allocate capital prudently. The mutual fund (hereinafter referred to as the "Fund") is structured as a long-term investment vehicle, primarily aimed at diversifying investments and mitigating the risks associated with individual security acquisitions. Unlike financial mechanisms offering guaranteed returns, such as savings accounts, subscribing to a mutual fund entails participating in the Fund's portfolio returns relative to your investment share, as well as bearing any associated losses.

In compliance with current regulatory requirements, distributors must classify investors' categories, assess investors' risk tolerance, and determine the risk level of the funds, providing appropriate matching advice. Note that discrepancies may exist between the Fund's risk descriptions in its legal documentation and the risk evaluations made by the distribution entity. Therefore, before making any investment decisions, investors are urged to carefully read and understand the product’s legal documents, including the Fund Contract, Prospectus, Summary of Fund Information, and Risk Disclosure Statement. This will ensure a thorough understanding of the risk-return dynamics and intrinsic attributes of the Fund. Investors should meticulously evaluate the Fund’s various risk factors and, considering their investment objectives, timelines, experience, and financial standing, conduct a comprehensive assessment of their risk tolerance. This will allow for informed and prudent investment decisions based on an intrinsic understanding of the product and suitability assessments provided by the distributors.

Pursuant to relevant legal frameworks, E Fund Management Co., Ltd., as the Fund Manager, hereby disseminates the following risk disclosure:

I. Depending on their investment objectives, the Fund is classified into various categories, including equity funds, balanced funds, bond funds, money market funds, fund-of-funds (FoF), and commodity funds. Each category offers differing expectations of return and associated risks. Generally, higher expected returns are often accompanied by higher risks.

II. Investors should achieve a robust understanding of the differences between systematic investment plans and traditional savings methods such as fixed deposits. Systematic investment plans are designed to promote long-term investment and average investment costs, but they do not insulate investors from market risks or guarantee returns. Thus, they should not be viewed as direct substitutes for traditional savings methods.

III. During its investment operations, the Fund may encounter various risks, including market risk, liquidity risk, management risk, tax risk, technological risk, and compliance risk. A specific risk to open-end funds is that of substantial redemptions—if the net redemption requests exceed 10% of the Fund's total share volume on any given business day, investors may experience delayed redemptions or may not be able to redeem all their shares promptly.

IV. Potential investment risks associated with the Fund include: (1) market risk; (2) specific risks associated with this Fund: the Fund is greatly affected by the systematic risk of the stock market; industry risks caused by changes in government policies and other factors, as well as the risk that the overall performance of healthcare stocks may be poor, and the risk that the fund's investment return may be lower than the performance comparison benchmark; the Fund may invest in the stocks of the Science and Technology Innovation Board, and may face delisting risk, market risk, liquidity risk and other unique risks, which may bring adverse effects or losses to the net value of the Fund; the risk of investing in depositary receipts; (3) liquidity risk; (4) potential inconsistencies between the Fund's risk descriptions in legal documents and evaluations by distributors; (5) management risk; (6) and other unforeseen risks.

V. The Fund Manager commits to managing and utilizing the Fund's assets with diligence, integrity, and honesty. However, the profitability or a minimum return on the Fund cannot be guaranteed. The Fund's historical performance and net asset values are not indicative of future performance. The performance of other funds managed by E Fund Management Co., Ltd. is not a guarantee for the performance of this Fund. Investors are reminded to adhere to the principle of "caveat emptor" when investing in funds and to bear the associated risks of fluctuations in the Fund’s operations and net asset values when making investment decisions. Neither the Fund Manager, the custodian, the distributors, nor affiliated entities make any commitments or guarantees regarding the Fund’s returns.

VI. The registration of the Fund with the China Securities Regulatory Commission (CSRC) does not imply any substantive judgment or guarantee of its value or returns, nor does it indicate that the Fund is risk-free. The Fund Manager manages and utilizes the Fund's assets adhering to principles of diligence, honesty, and credibility, but cannot guarantee profitability or a minimum return. Investors who purchase fund shares in accordance with the Fund Contract become unit holders and parties to the Fund Contract. Any disputes arising from or in relation to the Fund Contract should initially be resolved through negotiation and mediation. If negotiation fails, arbitration will be the final means of dispute resolution, as detailed in the Fund Contract. The Fund Contract, Prospectus, and Information Summary of this Fund have been publicly disclosed on the CSRC Fund Electronic Disclosure Website at http://eid.csrc.gov.cn/fund and on the Fund Manager's website at http://www.efunds.com.cn.

VII. Investors are advised to purchase or redeem Fund shares through the Fund Manager or other authorized institutions with fund sales qualifications. A list of such institutions can be found on the Fund Manager's website.